ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

TAF Prev Med Bull. 2009; 8(1): 75-82


One of the Major Problems in Tuberculosis Control: Adherence to Therapy

Belgüzar,Kara.



Abstract
Download PDF Post

Abstract: Although tuberculosis (TB) is a preventable and curable disease, approximately one third of the world’s population is infected with the TB bacillus. Tuberculosis is a major public health problem in especially developing countries. Nonadherence to TB therapy regimes is common, as treatment is difficult and requires long courses of multiple antibiotics. It is estimated that the rate of nonadherence to TB treatment ranges from 20 to 80%. Nonadherence to TB treatment is the most serious barrier in disease control because incomplete treatment may result in prolonged infectiousness, drug resistance, relapse and death. However, handling the factors affecting adherence to treatment for the patients may increase the efficiency of the treatment and help to reach better health outcomes. This article reviews evidence regarding adherence to TB treatment in patients and affecting factors and makes recommendations for health care professionals.

Key words: Tuberculosis, therapy, adherence

Article Language: Turkish English





Bibliomed Article Statistics

22
25
31
39
30
28
25
16
15
16
15
6
R
E
A
D
S

10

10

10

7

13

16

9

10

8

9

10

2
D
O
W
N
L
O
A
D
S
010203040506070809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.